SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Clinical trials for SMALL LYMPHOCYTIC LYMPHOMA (SLL) explained in plain language.
Never miss a new study
Get alerted when new SMALL LYMPHOCYTIC LYMPHOMA (SLL) trials appear
Sign up with your email to follow new studies for SMALL LYMPHOCYTIC LYMPHOMA (SLL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for blood cancers
Disease control CompletedThis study tested a combination of two drugs, acalabrutinib and pembrolizumab, in 161 people with different types of blood cancers like lymphoma and leukemia. The main goal was to check safety and see how well the treatment works. This is an early-stage study, so results help gui…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Phase: PHASE1, PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated May 17, 2026 04:33 UTC
-
New combo therapies show promise for japanese CLL patients
Disease control CompletedThis study tested two drug combinations (venetoclax plus obinutuzumab or ibrutinib) in 20 Japanese adults with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal was to see how well the treatments worked and how safe they were. P…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
CAR-T therapy Follow-Up study finds no new safety surprises
Knowledge-focused CompletedThis study followed 16 people who had already received a special immune cell treatment (CLBR001 CAR-T) for various blood cancers like lymphoma and leukemia. The goal was to see if any new or late side effects appeared over time and how long the treatment's effects lasted. It was …
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Knowledge-focused
Last updated May 06, 2026 16:02 UTC